EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Bruker Corporation (BRKR) fair value: what the stock is really worth

We calculate from audited financials what Bruker Corporation is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US1167941087

BC Bruker Corporation logo Some data Sep 18, 2026

Bruker Corporation

BRKR · US

Structural break: The valuation model sees a lasting decline in earnings power for this stock, the confidence band is broken. Treat the target with caution.

Weakest SetupStrongly overvalued and low quality.

!Fair value $8.51 · Strongly overvalued (−86%)
!Quality 34/100
!Mixed Growth (revenue 5y +11.6 %/yr)
!Loss-making · -0.3% net margin (TTM)
✓Moderate debt · generates free cash flow
·0.32% dividend yield
!Trails peers (2/14)
!Narrow moat 32/100
!Insider activity 46/100
!Evidence only medium, so the estimate is less certain
!The models disagree: range $8.31 to $19.66
!Weak on future: 14 out of 100
Watch Bruker Corporation for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$93.36 $29.21 Fair Value $8.51 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 18, 2026.

How to read this chart

60‑month range $29.21 – $93.36 · fair‑value band $8.31 – $19.66 · the $61.58 price screens above the $8.51 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 18, 2026.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.

Show more

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions. It operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. The company offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools; innovative nuclear magnetic resonance (NMR) and electron paramagnetic resonance (EPR) products; solutions for in-vivo processes and drug discovery; aftermarket solutions; solutions for lab automation and digitalization; mass spectrometry solution and test kits, DNA test strips, and fluorescence-based PCR technologies; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; services for transcriptional profiling and multiomic analysis; superconducting materials, such as metallic low temperature superconductors; multifilament round and rectangular LTS wires in both monolithic and wire-in-channel formats; designs and manufactures Cuponal; metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation was founded in 1960 and is headquartered in Billerica, Massachusetts.

Stock analysis

Bruker Corporation (BRKR) currently trades at $61.58, while our model-based Fair Value estimate is $8.51, implying the stock looks roughly 623.6% overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $16.15 per share, and 0 of the 14 models we run sit above the $61.58 price.

Bear case: the Dividend Discount group reads lowest at $2.27, and 14 of the 14 models stay below the price. Evidence for this calculation is medium.

Scenario range: $8.31 (bear) to $19.66 (bull), the price of $61.58 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Bruker Corporation reported revenue of $3.4B in FY2025 versus $2.4B in FY2021, a compound +9.2%/yr. Reported net income was −$8.6M in FY2025.

Key figures

Market cap $9.3B · P/S ratio 2.52 · EPS (TTM) $−0.2400 · Dividend yield 0.3% · Net margin −0.3% · Return on equity −0.4% · Return on assets (EBIT) 8.3% · Operating margin 6.2%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 52 out of 100 (low confidence).

What moves the price

The share trades near its 52-week high and 117% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 1% fair-value upside, at −86%, BRKR screens richer than that median.

Fair Value models

The price assumes far more growth than our models allow for, so the models scatter widely ($2.27 to $31.76). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $8.31 Fair Value $8.51 Bull $19.66
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings n/a $6.23 $17.56 73
EPV $2.14 $4.09 $5.77 71
5Y EBITDA Exit $10.00 $29.81 $54.89 70
All 14 models by family
DCF Models
Owner Earnings n/a $6.23 $17.56 73
5Y Revenue Exit $0.0900 $9.72 $22.98 63
5Y EBITDA Exit $10.00 $29.81 $54.89 70
10Y Revenue Exit n/a $5.34 $18.17 64
10Y EBITDA Exit $3.99 $19.61 $43.89 61
Earnings-Based
EPV $2.14 $4.09 $5.77 71
Dividend Discount
Gordon GGM $1.32 $2.62 $3.97 67
DDM Multi-Stage $1.32 $2.27 $2.77 67
Multiples
EV/EBIT $9.56 $16.15 $22.74 64
EV/EBITDA $21.27 $31.76 $42.25 66
EV/Revenue $3.90 $9.95 $15.99 50
Asset-Based
NCAV (Graham) $8.07 $10.81 $16.14 54
Growth DCF
Rev-Margin DCF $0.0900 $9.31 $20.95 64
Economic Profit
ROIC Compounder $2.14 $4.09 $5.77 70

Open the full fair value analysis →

Notify me when BRKR reaches fair value

Put BRKR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 34/100

Of which business quality 35 · Market factors (momentum, volatility) 70

Profitability 25
Margins and returns on capital today
Quality Growth 23
Are margins and returns improving?
Cashflow 15
Earnings quality: real cash, not paper profit
Fin. Strength 51
Balance sheet, leverage, solvency risk
Investment 32
Disciplined investing over empire-building
Low Volatility 22
Calm price path (market factor)
Momentum 87
Price trend over the last 3–12 months (market factor)
52W Momentum 96
Distance to the 52-week high (market factor)
Net Issuance 71
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 57/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+2.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+10.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Revenue growth 27 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
12.5% (2020) → 6.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+62.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+4.0%
Yearly sales growth analysts expect, extended to five years.
Forecast 2026 (sales)+4.4%
Forecast 2027 (sales)+4.3%
Projected 2028 (sales)+4.0%
Projected 2029 (sales)+3.7%
Projected 2030 (sales)+3.4%

BRKR screens 624% overvalued. Compare with Abbott Laboratories, →

Earlier news

News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare Bruker Corporation with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 354 stocks

Beats the industry median on 2/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 34 · Bottom 25%
Fair Value upside −54% · Below median
Profitability
Return on assets 3% · Above median
Net margin (TTM) 0% · Below median
Operating margin (TTM) 6% · Below median
Growth and dividend
Revenue growth 3% · Below median
Dividend yield (TTM) 0.3% · Bottom 25%
Balance sheet
Debt / equity 0.75× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 3.71× · Priciest 25%
P/S (TTM) 2.63× · Pricier than median
P/FCF 210.3× · Priciest 25%
EV/EBITDA 21.8× · Pricier than median
PEG 1.52× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 7
FUTURE (revenue growth)14 · sector 32
PAST (return on equity)0 · sector 7
HEALTH (low debt)62 · sector 97
DIVIDEND (yield)6 · sector 37

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $102.03 $74.79 −27%
Stryker Corporation SYK $281.50 $309.65 +10%
Medtronic plc MDT $93.75 $65.57 −30%
Boston Scientific Corporation BSX $43.87 $48.26 +10%
Edwards Lifesciences Corporation EW $85.74 $82.04 −4%
Siemens Healthineers AG SHL €38.42 €33.87 −12%
DexCom, Inc DXCM $86.45 $95.10 +10%
GE HealthCare Technologies Inc GEHC $63.49 $64.13 +1%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.80 ¥172.48 +10%
Koninklijke Philips N.V PHIA €21.54 €14.36 −33%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Bruker Corporation · Fair Value
$8.51 −624%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Bruker Corporation Fair Value". https://www.fairvalue-calculator.com/stock/BRKR

Frequently asked questions

Is Bruker Corporation (BRKR) overvalued or undervalued?
As of Sep 18, 2026, our model estimates a fair value of $8.51 versus a price of $61.58, about −86% upside (overvalued).
What is the fair value of BRKR?
Our model-based fair value for Bruker Corporation is $8.51 (as of Sep 18, 2026), built from audited fundamentals. The current price: $61.58.
What is the quality score of BRKR?
Bruker Corporation has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bruker Corporation (BRKR)?
Our model-based price target is the fair value of $8.51 (as of Sep 18, 2026) from 14 valuation models. Cautious scenario $8.31, optimistic scenario $19.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Bruker Corporation stock forecast for 2026?
Our models put fair value at $8.51, about −86% upside versus a price of $61.58 (overvalued). Cautious scenario $8.31, optimistic scenario $19.66. The calculation is refreshed regularly with new filings.
What is the revenue of Bruker Corporation (BRKR)?
Bruker Corporation reported trailing-twelve-month revenue of about $3.5B (latest available figure, as of Sep 18, 2026).
Does Bruker Corporation pay a dividend?
Bruker Corporation currently shows a dividend yield of about 0.32% relative to its recent price (as of Sep 18, 2026).
What growth is priced into Bruker Corporation (BRKR)?
For today's price to be fair in a discounted-cash-flow model, Bruker Corporation would have to grow free cash flow by +62.5 % per year for five years (discount rate 10.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.6 % per year. As of Sep 18, 2026.
What discount rate (WACC) does the fair value of BRKR use?
Our models discount Bruker Corporation at 10.0 %: a base by market capitalisation (mid), damped by beta 1.12, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Bruker Corporation that is +62.5 % per year a year over ten years, using the same discount rate (10.0 %) and the same formula as our fair value.
How much growth has Bruker Corporation (BRKR) delivered so far?
Over the past 5 years revenue at Bruker Corporation grew +11.6 % a year. The price currently implies +62.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Bruker Corporation (BRKR) growing?
The median revenue growth in the sector is +4.3 % a year. That is the yardstick for the growth priced into Bruker Corporation (+62.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Bruker Corporation (BRKR)?
The free-cash-flow yield on the price is 0.46 %: that much free cash flow Bruker Corporation produces per unit of market value. When it exceeds the discount rate of our models (10.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Bruker Corporation (BRKR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bruker Corporation it is $8.51 per share (as of Sep 18, 2026), against a price of $61.58. It is the blended result of 14 valuation models (cash flow, earnings, asset, dividend).
Is Bruker Corporation stock overvalued or undervalued in 2026?
As of Sep 18, 2026, BRKR trades above its calculated fair value: price $61.58, fair value $8.51, a gap of about −86% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BRKR?
No. The price is what the market pays today ($61.58); the fair value is what the company's own numbers justify ($8.51). For Bruker Corporation the two are $53.07 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bruker Corporation worth?
The market values Bruker Corporation at about $9.3B (market capitalisation, as of Sep 18, 2026). Per share that is $61.58; our models calculate a fair value of $8.51 per share.
What do the bullish and bearish scenarios say about BRKR?
Our models span a range for Bruker Corporation: cautious scenario $8.31, base $8.51, optimistic $19.66 per share (as of Sep 18, 2026, price $61.58). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the PEG ratio of BRKR?
The PEG ratio of Bruker Corporation is 1.52 (P/E divided by earnings growth, as of Sep 18, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Bruker Corporation (BRKR)?
Balance-sheet figures for Bruker Corporation (as of Sep 18, 2026): return on equity −0.4%, debt of 0.75 per unit of equity. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
How far is BRKR from its 52-week high?
Bruker Corporation trades at $61.58, about 4% below its 52-week high of $58.98 and 117% above the low of $28.41 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $8.51 is for.
Which stocks are comparable to Bruker Corporation?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bruker Corporation stock attractive at the current price?
The data as of Sep 18, 2026: price $61.58, calculated fair value $8.51 (−86%), Quality Score 34/100, from 14 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BRKR calculated?
We run Bruker Corporation through 14 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $8.51, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 16.1 % above its aggregate fair value. Bruker Corporation itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bruker Corporation (BRKR)?
The closing price on Sep 21, 2026 was $61.58. Our model-based fair value is $8.51, about −86% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bruker Corporation right now?
The price sits above even our optimistic bull case ($19.66). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range ($8.31 to $19.66) leaves room in how you read the outcome.
Where does the earnings growth of Bruker Corporation (BRKR) come from?
Earnings per share at Bruker Corporation grew +13.5 % a year from 2014 to 2025. Broken into its drivers: revenue per share +9.2 %, EBIT margin +3.0 %, tax rate −0.9 %, residual (interest, one-offs) +1.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Bruker Corporation

How large is the market capitalisation of Bruker Corporation (BRKR)?
The market capitalisation of Bruker Corporation is $9.3B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bruker Corporation (BRKR)?
The price-to-sales ratio of Bruker Corporation is 2.52 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bruker Corporation (BRKR)?
Earnings per share at Bruker Corporation are $−0.2400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bruker Corporation (BRKR)?
The dividend yield of Bruker Corporation is 0.3%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bruker Corporation (BRKR)?
The net margin of Bruker Corporation is −0.3% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bruker Corporation (BRKR)?
The return on equity (ROE) of Bruker Corporation is −0.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bruker Corporation (BRKR)?
On an EBIT basis the return on assets of Bruker Corporation is 8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bruker Corporation (BRKR)?
The operating margin of Bruker Corporation is 6.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bruker Corporation (BRKR)?
Revenue at Bruker Corporation is growing +2.7% versus a year earlier (3y avg +10.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bruker Corporation (BRKR)?
Earnings per share at Bruker Corporation are growing −81.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Bruker Corporation (BRKR) carry?
The net debt of Bruker Corporation is $1.7B (fiscal year 2025, ≈ 40.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Bruker Corporation in the live analysis

One click puts Bruker Corporation on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.